Personalized Medicine 9.0

Gene Therapy and Genome Editing

This changes everything!

South San Francisco Conference Center
Thursday 26 May 2016
8:00am - 7:30pm

http://personalizedmedicine.sfsu.edu

A San Francisco State University Biology Conference
Personalized medicine seeks to use genetic variation to develop new diagnostic tests and treatments and to identify the sub-groups of patients for whom they will work best. This approach can also help determine which groups of patients are more prone to developing some diseases and, ideally, help with the selection of lifestyle changes and/or treatments that can delay onset of disease or reduce its impact. This year, in our ninth annual conference on personalized medicine, we address the promise of technologies like genome editing for gene therapy and drug discovery. The correction of genetic disease has been elusive until very recently, but the process of genome editing through the CRISPR/Cas9 system has revolutionized the field with unprecedented speed, and unparalleled opportunities. CRISPR has also proved to be one of the most powerful tools in basic genetics and biology developed in the last century, and provides new ways to understand cellular function. We explore the science behind gene therapy and genome editing, the ethics of germline gene manipulation, and the implications for the future of the pharmaceutical industry and the human species.
Conference Program At-A-Glance

8:00  Breakfast & Networking
8:50  Introductory Remarks
     Michael A. Goldman, Ph.D., Chair, Department of Biology at SF State
     Host: Richard M. Lawn, Ph.D., Executive Director, Scientific Affairs, Audentes Therapeutics
9:00  Keynote: Gene therapy in action
     Barrie Carter, Ph.D., Vice President, Vector Biology, BioMarin Pharmaceutical Inc.
10:00 Break
10:30 Gene therapy: State of the science
     Fyodor Urnov, Ph.D., Vice President, Discovery and Translational Research, Sangamo BioScience
11:15 Technological advances in gene therapy and genome editing
     Eric Rhodes, Chief Technology Officer, Horizon Discovery
12:00 Lunch & Networking
1:10  Remarks:
     Keith J. Bowman, Ph.D., Dean, College of Science & Engineering, SF State
1:15  CRISPR – This changes everything!
     Andrew May, D.Phil., Chief Scientific Officer, Caribou Biosciences
2:00  A CRISPR approach to animal genome editing
     Soren Warming, Ph.D., Senior Scientist, Genentech, Inc.
2:45  Networking Break
3:15  CRISPR genome editing in stem cells to model human disease
     Kathryn N. Ivey, Ph.D., Assistant Professor of Pediatrics, University of California, San Francisco,
     and the Gladstone Institute
4:00  Panel: The state of clinical gene therapy
     Session Leader: Richard M. Lawn, Ph.D., Executive Director, Scientific Affairs, Audentes Therapeutics
     Barrie Carter, Ph.D., Vice President, Vector Biology, BioMarin Pharmaceutical Inc.
     Kathryn N. Ivey, Ph.D., Assistant Professor of Pediatrics, University of California, San Francisco,
     and the Gladstone Institute
     Andrew May, D.Phil., Chief Scientific Officer, Caribou Biosciences
     Eric Rhodes, Chief Technology Officer, Horizon Discovery
     Fyodor Urnov, Ph.D., Vice President, Discovery and Translational Research, Sangamo BioScience
     Soren Warming, Ph.D., Senior Scientist, Genentech, Inc.
     Chong Wing Yung, Ph.D., Advanced Research Scientist, Agilent Technologies
5:00  Ethical and regulatory aspects of genome editing & gene therapy: This could be dangerous!
     Janet D. Stemwedel, Ph.D., Professor & Chair, Department of Philosophy, San Jose State University
5:45  Closing Remarks
     Kevin Mullin, Speaker Pro Tempore & Chair, Select Committee on Biotechnology, California State Assembly
     Michael A. Goldman, Ph.D., Chair, Department of Biology at SF State
5:55  Reception, Student Posters & Awards
7:00  Close of conference
Thank you to our 2016 Sponsors

Platinum Partner

Partners

Sponsors

Supporters

Media Partners

2016 Organizing Committee:

Michael A. Goldman, Ph.D.
Professor & Chair
SF State Department of Biology

Dan Maher
Special Advisor to the CEO
BioMarin Pharmaceutical Inc.

Ken Hitchner
Vice President
BioMarin Pharmaceutical Inc.

John Wulf
President
New Frontier Life Sciences Consulting

Sally G. Pasion, Ph.D.
Associate Professor
SF State Department of Biology

Amy Waterhouse
Senior Director - Regulatory Affairs
BioMarin Pharmaceutical Inc.

Victoria Hines, Ph.D.
Executive Director – Product Development
BioMarin Pharmaceutical Inc.

Vince Anicetti
Sr. Vice President – Global Quality
Coherus BioSciences

Special thanks to the Staff of the Department of Biology and the College of Science & Engineering at SF State University, and the City of South San Francisco

Watch for Personalized Medicine 10.0 in 2017!

http://personalizedmedicine.sfsu.edu
dnamed@sfsu.edu

The Department of Biology at SF State University
Advancing global health & the biosphere